As cited above, the evolution of lung cancer therapy and the implementation of tyrosine kinase inhibitors (TKIs) and immunotherapy raised interest in evaluating ILD-LC actionable mutations and PD-L1 expression. This evidence concerns the gene CD274 and lung carcinoma.